Ashkon Software







 

RPRX - Repros Therapeutics Inc.


RPRX Stock Chart

RPRX Profile

Repros Therapeutics Inc. logo

Royalty Pharma plc, headquartered in New York, New York, operates as a leading buyer of biopharmaceutical royalties and a strategic funder of innovations within the biopharmaceutical industry in the United States. The company specializes in identifying, evaluating, and acquiring royalties associated with a wide range of biopharmaceutical therapies, fostering collaborations with diverse stakeholders including academic institutions, research hospitals, not-for-profits, small to mid-cap biotechnology firms, and established pharmaceutical companies.

Royalty Pharma's extensive portfolio includes royalties from approximately 35 marketed therapies and 10 developmental-stage product candidates spanning therapeutic areas such as rare diseases, cancer, neurology, infectious diseases, hematology, and diabetes. By investing in these royalties, the company plays a pivotal role in supporting the advancement of innovative treatments that address critical medical needs and improve patient outcomes.

In addition to its core activities in royalties, Royalty Pharma actively engages in strategic partnerships and acquisitions to expand its portfolio and enhance its position within the biopharmaceutical sector. The company's approach is rooted in rigorous due diligence and a commitment to long-term value creation through sustainable investments in biopharmaceutical innovations.

Founded in 1996, Royalty Pharma has established itself as a trusted partner and investor in the biopharmaceutical industry, leveraging its deep expertise and extensive network to drive growth and innovation. With a dedicated focus on advancing therapies that make a meaningful impact on global healthcare, Royalty Pharma continues to shape the future of biopharmaceutical development and investment.

RPRX Revenue Chart

RPRX Earnings


Stock Sector: Drugs: Biotechnology

 

Copyright © 2000-2024, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer